Genetic Susceptibility to Cardiovascular Disease in Patients on Kidney Dialysis

Completed

Conditions studied: End Stage Renal Disease, ESRD

In brief

This study, done in collaboration with Johns Hopkins University School of Public Health in Baltimore, Maryland, will examine the role of genes in the development of atherosclerotic cardiovascular disease (CVD) in patients undergoing kidney dialysis. The rate of illness and death from CVD among patients on dialysis is extraordinarily high, accounting for about 50 percent of deaths. Blood levels of inflammatory markers are elevated in these patients, strongly predicting illness and death from CVD. The discovery of gene variants related to the inflammatory process in atherosclerotic CVD may lead to better medical treatments and improved survival in patients with end-stage kidney disease. Participants of John's Hopkins University's CHOICE (Choices for Healthy Outcomes in Caring for End-Stage Renal Disease) program are included in this study. Blood samples previously collected from these patients will be analyzed in the laboratory for genes that might be associated with the inflammatory process and atherogenesis.

Key facts

Study ID

NCT00340119

Run by

National Cancer Institute (NCI)

People needed

871

Starts

2005-03-21

Expected to finish

2012-03-01

Last updated by the study team

2017-07-02

Who can join

Age: 19 and older. Sex: any. Healthy volunteers: not accepted.

You may not qualify if…

• The entire set of 871 samples available to the LGD will be analyzed. No subject will be excluded.

Where it is running

• Johns Hopkins University — Baltimore, Maryland, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.